Related Experiment Videos
CYP2D6 and CYP2C19 genotypes in an elderly Swedish population
H Yamada1, M L Dahl, L Lannfelt
1Department of Medical Laboratory Sciences and Technology Huddinge University Hospital, Sweden.
European Journal of Clinical Pharmacology
|October 17, 1998
Summary
Genetic variations in drug-metabolizing enzymes CYP2D6 and CYP2C19 do not influence longevity. These findings suggest similar drug pharmacokinetics in elderly and younger adults.
Area of Science:
- Pharmacogenomics
- Gerontology
- Drug Metabolism
Background:
- Oxidative drug metabolism is crucial for drug clearance.
- Genetic polymorphisms in CYP2D6 and CYP2C19 affect drug metabolism efficiency.
- Understanding these polymorphisms in the elderly is important for safe and effective pharmacotherapy.
Purpose of the Study:
- To investigate the frequencies of CYP2D6 and CYP2C19 genetic polymorphisms in healthy elderly individuals.
- To compare these frequencies with those in younger control populations.
- To determine if these genetic variations impact the likelihood of reaching advanced age.
Main Methods:
- Genotyping of 83 healthy elderly Swedish subjects (80-98 years) for CYP2D6 and CYP2C19 polymorphisms.
- Utilizing allele-specific polymerase chain reaction (PCR).
- Comparison with control groups of younger healthy volunteers (n=248 for CYP2D6, n=162 for CYP2C19).
Main Results:
- No significant differences in defect allele frequencies (CYP2D6*3, *4; CYP2C19*2, *3) between elderly and younger groups.
- Genotype and predicted phenotype frequencies were also comparable.
- CYP2D6 and CYP2C19 genotypes do not appear to be major determinants of longevity.
Conclusions:
- The genetic makeup related to CYP2D6 and CYP2C19 metabolism is similar in elderly and younger populations.
- No age-related genetically determined differences in drug pharmacokinetics are anticipated for drugs metabolized by these enzymes.
- This suggests that standard dosing considerations for these enzymes may apply across age groups.